Fig. 4.

PK and PD relationship post-single dose of DZD1516 in BT474C1-Luci Mono1 SC xenograft mice model. A single dosing of DZD1516 at 25, 50, 150 mg/kg was administrated when the tumor volume reached 200–600 mm³. Plasma and tumor tissues were collected at 0.25, 2, 6, and 24 h post-dosing to analyze the PK/PD correlation. The pHER2 expression in tumor tissues was detected by immunohistochemistry (IHC) and normalized to the vehicle control group. Each time point had tumor tissues from three mice to detect the pHER2 signal. PK pharmacokinetics, PD pharmacodynamics, SC subcutaneous